Canada, Qatar and South Korea Approve PharmaMar’s Zepzelca® in combination with Atezolizumab for First-Line Maintenance Treatment of Small Cell Lung Cancer

Canada, Qatar and South Korea are the latest countries to approve the commercialization of the treatment. The treatment is available now in 18 territories worldwide. PharmaMar (MSE: PHM) announced today that health authorities in Canada, Qatar and South Korea have approved Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) for the maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. The approvals by the Canada’s Health Products and Food Branch (HPFB), the Health Qatar Ministry of Public Health (MoPH) and the Ministry of Food and Drug Safety of South Korea (MFDS) are based on the positive results from the Phase 3 IMforte[1] trial. With these latest authorizations, the lurbinectedin–atezolizumab combination is now approved in 18 territories worldwide, including the European Union and the United States. [1] Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial – The Lancet

The release as fetched from its publisher. pharmamar.com ↗